Last reviewed · How we verify
An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 After Oral Administration to Healthy Volunteers
The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 4 |
| Start date | 2008-02 |
| Completion | 2008-07 |
Conditions
- Anxiety
Interventions
- AZD7325
- Radioligand (11C) flumazenil
Primary outcomes
- Positron emission tomography using the radioligand (11C)flumazenil — 4 times per subject
Countries
Sweden